Genetic Polymorphism, Metabolic Syndrome, Schizophrenia
Conditions
Keywords
schizophrenia, metabolic side effect, clozapine, genetic polymorphism
Brief summary
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
Detailed description
The use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes. The prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. The high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant. The genotypes of the multiple gene such as HTR2C, LEP, adrenergic receptor,PPAR,GNB3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome) in patients using antipsychotics. We are going to investigate whether those multiple genetic polymorphisms are associated with the metabolic side effects in patients taking clozapine.
Interventions
None listed
Sponsors
Seoul National Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age 18-65 * who can understand and sign the informed consent
Exclusion criteria
* who refuse to participate this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The associations between multiplegenetic polymorphisms (HTR2C,leptin,adrenergic receptor,PPAR,GNB3) and the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome) | more than 1 year after starting clozapine |
Countries
South Korea
Contacts
Primary ContactShi Hyun Kang, M.D.
Outcome results
None listed